Search the Newsreel

ClearPoint Neuro (NASDAQ:CLPT) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded ClearPoint Neuro (NASDAQ:CLPT) to a "strong sell" rating, despite other analysts having a mixed view with a consensus "Hold" rating and a target price of $25.67. The downgrade follows ClearPoint Neuro missing its quarterly earnings expectations, reporting an adjusted …

Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Clearpoint Neuro Inc (CLPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Alto Neuroscience Inc (ANRO), detailing analyst ratings and EPS expectations. Ten analysts currently rate ANRO as a "Strong Buy" with a target price indicating a potential 24.11% upside. The previous quarter's EPS was -$0.47, beating the market …

Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Neurocrine Biosciences, Inc. (NBIX), including its current price, historical data, financial performance, analyst ratings, and company overview. It highlights key products like INGREZZA and several pipeline candidates for neurological and psychiatric disorders. The company's market …

Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview

Neuronetics Inc is projected to report a loss of 12 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation. Readers can access the full article through TradingView.

Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jupiter Neurosciences Inc (JUNS), indicating that no earnings forecast score is currently available, while the industry average is 8.10. Based on one analyst, the stock has a "Buy" rating with a target price of 25.000, representing 0.00% …

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

Promis Neurosciences (NASDAQ:PMN) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $31.50. Despite this positive outlook, the company reported a quarterly loss of $1.26 per share, missing consensus estimates, and analysts anticipate a full-year loss …

ProMIS Neurosciences Inc (PMN) Stock News Today

This article provides an update on ProMIS Neurosciences Inc (PMN) stock, noting a recent increase of 10.35%, bringing its share price to 14.710 USD. The platform, TradingKey, states that more news, earnings reports, analyst ratings, and key developments for PMN are coming soon. The …

Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares

Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc. (PMN), purchased 2,280 common shares at $13.30 each on August 5, 2026. This open market transaction increased her direct holdings to 6,221 common shares. The filing was classified as neutral in impact and positive in …

Minerva Neurosciences Releases Q2 2026 Financial Results

Minerva Neurosciences (NERV) reported its Q2 2026 financial results, showing a narrower loss of $0.14 per share, an improvement from $0.43 in Q2 2025. The company posted a net income of $17.5M, reflecting progress in managing R&D spending while advancing its CNS therapies. Analysts …

Neuropace Inc (NPCE) Stock News Today

This page from TradingKey provides current stock information for Neuropace Inc (NPCE), including its stock price, market cap, and links to financial data, forecasts, and ownership details. As of the latest update, the stock was trading at $14.830, up 6.69%, with a market cap …

Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal …

Clearpoint Neuro Inc (CLPT) Stock News Today

Minerva Neurosciences, Inc. Q2 2026: Net income $17.47M, EPS $(0.14) — 10-Q Summary

Minerva Neurosciences, Inc. reported a net income of $17.47 million for Q2 2026, a significant improvement from a loss in the previous year, with diluted loss per share narrowing to $(0.14). The company initiated its C19 Phase 3 trial for roluperidone, increased R&D spending, …

Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences reports $17.5 million Q2 net income as Phase 3 trial continues

Minerva Neurosciences (NERV) announced a Q2 2026 GAAP net income of $17.5 million. The company's Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia, is ongoing, with topline efficacy data expected in mid-2027 and mid-2028 for its two phases. The report also detailed …

Minerva Neurosciences (Nasdaq: NERV) swings to Q2 profit on warrant gain

Minerva Neurosciences reported a Q2 2026 GAAP net income of $17.5 million, or $0.36 per basic share, primarily due to a $27.6 million non-cash gain from a warrant liability fair value change. Despite this, the adjusted non-GAAP net loss widened to $7.8 million, reflecting …

Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Buy" from Analysts

Firefly Neuroscience Inc (AIFF) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neueon Corp Consolidated June 2026 Net Sales at Rs 0.06 crore, down 98.63% Y-o-Y

Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neuphoria Therapeutics Inc (NEUP) has an earnings forecast score of 6.00, placing it 327 out of 385 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00 for NEUP, with one analyst recommending a "Hold" rating. The company's …

Entropy Neurodynamics Director Herwig Janssen Receives Shares in Lieu of Cash Fees

Jupiter Neurosciences, Inc. (JUNS) Stock Price, News, Quote & History

Jupiter Neurosciences, Inc. (JUNS) stock was trading at $5.30, down 5.90%, as of 1:45:04 p.m. EDT. The company announced a 1-for-75 reverse stock split effective August 7, 2026. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapeutics for central nervous system disorders …

Entropy Neurodynamics Boosts Director Equity Through Share-Based Fees

Entropy Neurodynamics Issues New Shares in Lieu of Directors’ Fees

Earnings Preview: Neuronetics to Report Financial Results Pre-market on August 11

Neuronetics is scheduled to release its financial results pre-market on August 11. Analysts are anticipating an earnings per share (EPS) of -$0.12, with revenue projected to be around $15.54 million. Investors will be closely watching these figures for insights into the company's performance.

Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11

This article announces that NeuroPace is scheduled to release its financial results after the market closes on August 11. Investors and analysts will be keen to review the company's performance and outlook during the upcoming earnings call.

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

Promis Neurosciences (PMN) is expected to report its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting a loss of $1.3786 per share. This follows a larger-than-expected loss in the previous quarter. Despite mixed analyst views, the company holds a …

California State Teachers Retirement System Purchases 1,760 Shares of NewMarket Corporation $NEU

The California State Teachers Retirement System increased its stake in NewMarket Corporation by 23.6% in the first quarter of 2026, acquiring an additional 1,760 shares to hold a total of 9,210 shares valued at $5.9 million. This move comes as institutional investors collectively own …

Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com

This article reports on a Form 8K filing by Jupiter Neurosciences Inc. for August 6th. The content is very brief, mainly consisting of the headline and a reference to Reuters, indicating it's an announcement of the filing rather than an analysis of its contents. …

Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN)

NeuroSense Therapeutics (NASDAQ: NRSN) has successfully completed the Pre-NDS process with Health Canada for PrimeC, its lead ALS therapeutic candidate. The company aims to file a New Drug Submission (NDS) in December 2026, with Health Canada indicating no concerns with the proposed timeline and …

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Therapeutics announced it has completed the Pre-NDS process with Health Canada for PrimeC, its lead therapeutic candidate for ALS, and is targeting a New Drug Submission (NDS) filing in December 2026. This follows alignment with Health Canada on the submission's content and structure. …

Alto Neuroscience stock hits all-time high at 29.34 USD By Investing.com

Alto Neuroscience Inc. (ANRO) stock reached an all-time high of $29.34 and currently trades at $29.10, near its 52-week high, with a market capitalization of $1.09 billion. The stock has surged 840.52% in the past year, reflecting strong investor confidence despite being unprofitable according …

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently missed its second-quarter earnings expectations, with revenues 15% below forecasts and statutory losses increasing significantly. This has led analysts to downgrade revenue estimates for 2026 and project higher per-share losses, resulting in a 9.4% reduction in the consensus price …

Analysts Have Lowered Expectations For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Latest Results

ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently released its latest quarterly results, leading analysts to significantly reduce their earnings forecasts for the company. Despite the downward revisions, the consensus price target remains largely unchanged at US$17.17, suggesting that analysts still see potential for share price appreciation. …